Recent Updates — NTHI

Steven L. Giannotta resigned from the board effective October 9, 2026, citing no disagreements with company operations. The board appointed Ali Mohammad Ahmad Alabedin, Group Head of Islamic Banking at First Abu Dhabi Bank, to fill the vacancy as a Class I director serving until the 2029 annual meeting. This leadership change coincides with NeOnc's expansion in the UAE, where it has received Investigational New Drug authorizations for its lead candidates NEO100 and NEO212 from the Department of Health – Abu Dhabi. NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers.

NeOnc Technologies Holdings announced a press release scheduling an in-person End-of-Phase 1 Type B meeting with the U.S. Food and Drug Administration for November 17, 2026, concerning its investigational drug NEO212. The company plans to seek FDA feedback on clinical development program updates, including patient population, trial design, endpoints, dose selection, and evidence needed for future marketing applications. This follows the completion of Phase 1 dose-escalation, where 610 mg was selected as the recommended Phase 2 dose after dose-limiting toxicity at 810 mg. The filing is not material as it merely announces a scheduled regulatory discussion without confirming trial designs or approvals. NeOnc Technologies Holdings operates in the biopharmaceutical industry and develops therapies for central nervous system cancers.

NeOnc Technologies Holdings redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for approximately $5.79 million ($965 per share) on September 15, 2026, using proceeds from a recent registered direct offering. The company filed an Elimination of Certificate of Designation with Delaware to terminate the preferred stock designation effective September 18, 2026, eliminating potential dilution and simplifying its capital structure before discounted conversion features became available. NeOnc Technologies Holdings is a clinical-stage biopharmaceutical company developing novel therapies for central nervous system cancers.

NeOnc Technologies Holdings, Inc. entered into a securities purchase agreement for a registered direct offering of common stock and warrants to institutional investors. The company sold 2,610,715 shares of common stock, pre-funded warrants for 960,715 additional shares, and accompanying warrants for 3,571,430 shares at a combined price of $4.20 per share and warrant. Gross proceeds are approximately $15 million before fees. The closing occurred on September 10, 2026. Proceeds will fund working capital and redeem Series A Convertible Preferred Stock. Warrants have a five-year term with a $4.20 exercise price. CEO and CMO executed 90-day lock-up agreements. NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers.